FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156302506> ?p ?o ?g. }

• W2156302506 endingPage "104" @default.
• W2156302506 startingPage "98" @default.
• W2156302506 abstract "Purpose To determine the efficacy and tolerability of gemcitabine (GEM)-concurrent chemoradiotherapy (CCRT) vs. 5-fluorouracil (5-FU) CCRT for locally advanced pancreatic cancer. Methods and materials Thirty-four patients with locally advanced pancreatic cancer were studied. Eighteen patients were randomized to receive GEM CCRT (600 mg/m2/wk for 6 weeks) and 16 patients to receive bolus 5-FU CCRT (500 mg/m2/d for 3 days repeated every 2 weeks for 6 weeks). All patients were to receive 3D-CRT 50.4–61.2 Gy at 1.8-Gy/d fractions and GEM (1000 mg/m2 weekly for 3 weeks repeated every 4 weeks) after RT. Results The median survival and median time to progression were 14.5 months and 7.1 months for the GEM CCRT group and 6.7 months and 2.7 months for the 5-FU CCRT group (p = 0.027 and p = 0.019, respectively). The quality-adjusted life month survival time was 11.2 ± 0.5 months for GEM CCRT and 6.0 ± 0.3 months for 5-FU CCRT patients (p <0.001). The response rate was 50% (four complete responses and five partial responses) for GEM CCRT and 13% (two partial responses) for 5-FU CCRT (p = 0.005). Pain control was 39% for GEM CCRT and 6% for 5-FU CCRT (p = 0.043). Grade 3-4 neutropenia (34% vs. 19%), thrombocytopenia (0% vs. 7%), nausea (33% vs. 31%), vomiting (17% vs. 19%), hospitalization days per month of survival (7.4 ± 1.7 days vs. 8.0 ± 1.3 days), and full dose of RT received (78% vs. 75%) were not significantly different between the GEM CCRT and 5-FU CCRT patients. Conclusion GEM CCRT appears more effective than 5-FU CCRT for locally advanced pancreatic cancer and has comparable tolerability." @default.
• W2156302506 created "2016-06-24" @default.
• W2156302506 creator A5026090288 @default.
• W2156302506 creator A5034260893 @default.
• W2156302506 creator A5042673919 @default.
• W2156302506 creator A5047332056 @default.
• W2156302506 creator A5050819212 @default.
• W2156302506 creator A5054235677 @default.
• W2156302506 creator A5064580973 @default.
• W2156302506 creator A5077328471 @default.
• W2156302506 creator A5091691544 @default.
• W2156302506 date "2003-09-01" @default.
• W2156302506 modified "2023-10-17" @default.
• W2156302506 title "Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study" @default.
• W2156302506 cites W1894182878 @default.
• W2156302506 cites W1931508686 @default.
• W2156302506 cites W1940632416 @default.
• W2156302506 cites W1954948139 @default.
• W2156302506 cites W2016236483 @default.
• W2156302506 cites W2036586620 @default.
• W2156302506 cites W2043046437 @default.
• W2156302506 cites W2044573147 @default.
• W2156302506 cites W2059568689 @default.
• W2156302506 cites W2061877333 @default.
• W2156302506 cites W2083513265 @default.
• W2156302506 cites W2087650046 @default.
• W2156302506 cites W2090721857 @default.
• W2156302506 cites W2260988755 @default.
• W2156302506 cites W4236096037 @default.
• W2156302506 doi "https://doi.org/10.1016/s0360-3016(03)00435-8" @default.
• W2156302506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12909221" @default.
• W2156302506 hasPublicationYear "2003" @default.
• W2156302506 type Work @default.
• W2156302506 sameAs 2156302506 @default.
• W2156302506 citedByCount "195" @default.
• W2156302506 countsByYear W21563025062012 @default.
• W2156302506 countsByYear W21563025062013 @default.
• W2156302506 countsByYear W21563025062014 @default.
• W2156302506 countsByYear W21563025062015 @default.
• W2156302506 countsByYear W21563025062016 @default.
• W2156302506 countsByYear W21563025062017 @default.
• W2156302506 countsByYear W21563025062018 @default.
• W2156302506 countsByYear W21563025062019 @default.
• W2156302506 countsByYear W21563025062021 @default.
• W2156302506 countsByYear W21563025062022 @default.
• W2156302506 countsByYear W21563025062023 @default.
• W2156302506 crossrefType "journal-article" @default.
• W2156302506 hasAuthorship W2156302506A5026090288 @default.
• W2156302506 hasAuthorship W2156302506A5034260893 @default.
• W2156302506 hasAuthorship W2156302506A5042673919 @default.
• W2156302506 hasAuthorship W2156302506A5047332056 @default.
• W2156302506 hasAuthorship W2156302506A5050819212 @default.
• W2156302506 hasAuthorship W2156302506A5054235677 @default.
• W2156302506 hasAuthorship W2156302506A5064580973 @default.
• W2156302506 hasAuthorship W2156302506A5077328471 @default.
• W2156302506 hasAuthorship W2156302506A5091691544 @default.
• W2156302506 hasConcept C121608353 @default.
• W2156302506 hasConcept C126322002 @default.
• W2156302506 hasConcept C197934379 @default.
• W2156302506 hasConcept C2776694085 @default.
• W2156302506 hasConcept C2777063308 @default.
• W2156302506 hasConcept C2777909004 @default.
• W2156302506 hasConcept C2778375690 @default.
• W2156302506 hasConcept C2778424827 @default.
• W2156302506 hasConcept C2780210213 @default.
• W2156302506 hasConcept C2780258809 @default.
• W2156302506 hasConcept C2780456651 @default.
• W2156302506 hasConcept C2780580376 @default.
• W2156302506 hasConcept C2780852908 @default.
• W2156302506 hasConcept C526805850 @default.
• W2156302506 hasConcept C71924100 @default.
• W2156302506 hasConcept C90924648 @default.
• W2156302506 hasConceptScore W2156302506C121608353 @default.
• W2156302506 hasConceptScore W2156302506C126322002 @default.
• W2156302506 hasConceptScore W2156302506C197934379 @default.
• W2156302506 hasConceptScore W2156302506C2776694085 @default.
• W2156302506 hasConceptScore W2156302506C2777063308 @default.
• W2156302506 hasConceptScore W2156302506C2777909004 @default.
• W2156302506 hasConceptScore W2156302506C2778375690 @default.
• W2156302506 hasConceptScore W2156302506C2778424827 @default.
• W2156302506 hasConceptScore W2156302506C2780210213 @default.
• W2156302506 hasConceptScore W2156302506C2780258809 @default.
• W2156302506 hasConceptScore W2156302506C2780456651 @default.
• W2156302506 hasConceptScore W2156302506C2780580376 @default.
• W2156302506 hasConceptScore W2156302506C2780852908 @default.
• W2156302506 hasConceptScore W2156302506C526805850 @default.
• W2156302506 hasConceptScore W2156302506C71924100 @default.
• W2156302506 hasConceptScore W2156302506C90924648 @default.
• W2156302506 hasIssue "1" @default.
• W2156302506 hasLocation W21563025061 @default.
• W2156302506 hasLocation W21563025062 @default.
• W2156302506 hasOpenAccess W2156302506 @default.
• W2156302506 hasPrimaryLocation W21563025061 @default.
• W2156302506 hasRelatedWork W1996538874 @default.
• W2156302506 hasRelatedWork W2007528217 @default.
• W2156302506 hasRelatedWork W2022480437 @default.
• W2156302506 hasRelatedWork W2107962449 @default.
• W2156302506 hasRelatedWork W2166710064 @default.

• next